Marie Bosslett, Assistant Editor

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of February.

BE HEARD long-term data show bimekizumab (Bimzelx) IL‑17A/F reduces hidradenitis suppurativa draining tunnels while boosting IHS4 and quality of life.

A JAMA Dermatology study found that US veterans with documented Agent Orange exposure had approximately 30% higher odds of developing acral melanoma compared with unexposed veterans.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news on phase 3 remibrutinib data for CIndU subtypes, psoriasis “super responders” on risankizumab, the approval of difamilast ointment, and more.

Thrasyvoulos Tzellos, MD, PhD, explains HS’s progressive toll and how UCB’s BE HEARD bimekizumab data shows durable tunnel reduction and lasting disease improvement.

At IMCAS, Anne-Cécile Chevrier revealed new Galderma data on menopause and skin, urging earlier education and proactive treatment choices.

Alphyn Biologics advances zabalafin hydrogel for MC, aiming for painless relief by clearing lesions and itch in pediatric patients.

Neal Bhatia, MD, explores denifanstat for acne—oral FASN inhibition that curbs sebum, boosts outcomes, and may be an alternative to antibiotics or retinoids.

BEACON phase 2 shows brepocitinib delivers dramatic, low-placebo CSAMI improvements with strong safety, Misha Rosenbach, MD reports, boosting hope for cutaneous sarcoidosis.

Novartis reports RemIND phase 3 success and submits a supplemental New Drug Application to the FDA for symptomatic dermographism.

This review of the latest dermatological studies includes insights on racial differences in PCOS-related teenage acne, CVD in patients with HS and lymphedema, propranolol for infantile hemangioma, and more.

A new US consensus clarifies chronic hand eczema (CHE) diagnosis and stepwise care, highlighting FDA-approved treatment and patient-reported outcomes.

Misha Rosenbach, MD, discussed the burden of cutaneous sarcoidosis (CS) and how emerging therapies like brepocitinib could fill this clinical need.

Real-world data from Saudi Arabia show vitiligo combination therapy with narrowband UVB or Janus kinase inhibitors drives steeper VASI improvement than monotherapy.

Real-world data on psoriasis super responders show that risankizumab drives complete skin clearance for up to 2.5 years.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

In case you missed it, this week we had news on Biofrontera’s sNDA for Ameluz PDT in superficial BCC, 52-week data on rezpegaldesleukin for AD, the FDA's latest iPLEDGE REMS updates, and more.

PDPA’s 2025 survey, led by president Jamie Restivo, PA-C, reveals dermatology PA pay trends, productivity bonuses, benefits gaps, and satisfaction drivers shaping retention.

As we celebrate Valentine's Day, Mona Shahriari, MD, FAAD; Neal Bhatia, MD; Peter Lio, MD; Lisa Swanson, MD; Lawrence Schachner, MD; Julie Karen, MD; and Glynis Ablon, MD, FAAD, share why they love dermatology.

Des Fernandes, MBBCh, FRCS (Edin), pioneered microneedling as a safe skin regeneration therapy, demonstrating collagen gains and improved scars when paired with vitamins A and C.

LILAC data shows litifilimab rapidly improves CLE skin scores, fueling AMETHYST phase 3 and supporting FDA breakthrough for cutaneous lupus patients.

At a recent IMCAS symposium with Merz Aesthetics, Bianca Viscomi, MD, revealed how menopause and skin collide through collagen loss, confidence dips, and multimodal fixes.

DISCREET phase 3 research shows oral apremilast eases genital psoriasis symptoms, improving itch, clearance, and sexual quality of life through 32 weeks.

This review of the latest dermatological studies includes insights on lichen planus in family members, "washcloth withdrawal," the use of shiitake mushroom extract in dermatology, and more.

FDA eases iPLEDGE REMS for isotretinoin acne care, allowing some at-home pregnancy tests and fewer lockouts to reduce administrative burden.

Catch up on the health and dermatology-related commercials that aired during the 2026 Super Bowl.

REZOLVE-AD shows rezpegaldesleukin delivers durable atopic dermatitis control with monthly or quarterly dosing, supporting Nektar’s phase 3 plans.

In omalizumab-resistant chronic spontaneous urticaria (CSU), tofacitinib rapidly calmed symptoms, but relapses varied.